**This article is part of the Spotlight Issue on Inherited Conditions of Arrhythmia.**

1. Introduction
===============

The cardiac voltage-gated sodium channel (Na~V~1.5) encoded by the *SCN5A* gene, is responsible for the fast, initial upstroke of the action potential and as such is a critical determinant of cardiomyocyte excitability and conduction of the electrical impulse through the myocardium. Mutations in *SCN5A* are a long-established cause of a broad spectrum of inherited electrical disorders associated with sudden cardiac death, including long QT syndrome type 3 (LQT3), Brugada syndrome (BrS), progressive and non-progressive cardiac conduction disease (CCD), atrial fibrillation (AF), and sick sinus syndrome.[@cvaa082-B1]^,^[@cvaa082-B2] In addition to these electrical manifestations, consequences of sodium channel dysfunction may also include structural cardiac abnormalities that range from (micro)structural degenerative changes in the myocardium,[@cvaa082-B3] to dilated cardiomyopathy (DCM)[@cvaa082-B6]^,^[@cvaa082-B7] and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/ARVD).[@cvaa082-B8] Not uncommonly, inherited defects in *SCN5A* also manifest with a combination of these clinical phenotypes.[@cvaa082-B11]^,^[@cvaa082-B12]

Considerable knowledge has been gained into the function of Na~V~1.5 and its role in disease through the study of specific *SCN5A* variants found in patients. Clinical phenotypes associated with *SCN5A* mutations have so far been explained by defects in channel expression, trafficking, or its biophysical properties and these defects have been categorized into those that cause a loss or gain of channel function, or a combination of the two. Yet, some of these Na~V~1.5-related disorders, in particular structural abnormalities, cannot be directly or solely explained on the basis of defective Na~V~1.5 expression or biophysics.[@cvaa082-B1]^,^[@cvaa082-B2] While factors other than the *SCN5A* genetic defect itself, such as the inheritance of other genetic factors, undoubtedly play a role in modulating the different phenotypes and severity of *SCN5A* mutations, an emerging concept that may explain the large disease spectrum associated with *SCN5A* mutations centres around the multifunctionality of the sodium channel complex. While classically considered in light of the essential role of the channel in mediating electrical activity in the heart, in this alternative view, mutations affecting the sodium channel are considered to lead to disease by affecting processes that are independent of its canonical ion-conducting role. While some of these processes have been studied in detail, others, particularly those mediated through protein--protein interactions within the sodium channel complex await elucidation. A more complete understanding of the various functions of Na~V~1.5 in cardiomyocytes will undoubtedly favour the development of novel therapeutic approaches for inherited rhythm disorders and possibly in acquired disturbances of sodium channel function as occurs in ischaemia and heart failure. We here first provide a brief description of the cardiac sodium channel and a succinct overview of inherited disorders associated with Na~V~1.5 dysfunction. We subsequently review in detail current knowledge of the multiple functions of Na~V~1.5 and propose a new classification for these various functional roles of Na~V~1.5. These include direct ionic effects of sodium influx on cardiomyocyte electrophysiology, indirect ionic effects of sodium influx on intracellular ion homeostasis and signalling, and non-ionic effects of Na~V~1.5 independent of sodium influx. In particular, we discuss their respective contribution to the detrimental effects of cardiac sodium channel dysfunction.

2. The cardiac sodium channel: the pillar of action potential initiation
========================================================================

2.1. Sodium channel structure and function
------------------------------------------

The plasma membrane being a natural barrier to the passage of most large polar molecules and ions, membrane transport proteins assure travel across the bilayer. In cardiomyocytes, the voltage-gated, pore-forming alpha subunit of the cardiac sodium channel Na~V~1.5 (encoded by the *SCN5A* gene) is a transmembrane protein allowing the passage of sodium ions from the extracellular to the intracellular space.[@cvaa082-B13] It is composed of a cytoplasmic N-terminus, four transmembrane domains (DI--DIV) interconnected by cytoplasmic and extracellular loops, and a cytoplasmic C-terminal domain. The homologous DI--DIV domains each comprise six segments (S1--S6), of which S5 and S6 form the ion-conducting channel pore, and the highly charged S4 segment acts as the voltage sensor (*Figure [1](#cvaa082-F1){ref-type="fig"}*, upper panel).[@cvaa082-B14] The resting membrane potential of a cardiomyocyte is around −90 mV, which is determined by the equilibrium potential of potassium. At this voltage, the sodium channel is closed. As Na~V~1.5 is voltage-sensitive, a small depolarization of the membrane causes the charged segments S4, the voltage sensors, to move outward leading to opening of the channel pore formed by segments S5 and S6 and the linker between them. The rapid activation of Na~V~1.5 causes sodium ions to flow into the cell along the electrochemical gradient generating a large inward current (peak sodium current). The net charge of sodium ions entering the cell further depolarizes the membrane thereby initiating phase 0 of the action potential and is essential for cardiac excitability (*Figure [1](#cvaa082-F1){ref-type="fig"}*, lower panels).[@cvaa082-B13]^,^[@cvaa082-B15] Following activation, fast and complete Na~V~1.5 channel inactivation ensures proper repolarization, mediated by the DIII--DIV intracellular loop, the extracellular S5--S6 linker, and the C-terminal domain of the channel.[@cvaa082-B16]^,^[@cvaa082-B17] Because of the fast activation and fast inactivation of the sodium channel, the peak sodium current is brief (\<1 ms) under normal physiological conditions. A small fraction of channels, however, do not completely inactivate and a small sodium current persists throughout the duration of the action potential, called the 'persistent' or 'late' sodium current (I~Na,L~).[@cvaa082-B18] Many studies have now established that late sodium current significantly contributes to action potential duration in cardiomyocytes of different mammalian species (including human) and that it is enhanced in cardiac diseases.[@cvaa082-B18] In a recent study, Jiang *et al.*[@cvaa082-B23] used cryo-electron microscopy to solve the molecular structure of Na~V~1.5 at a resolution of 3.2--3.5 Angstroms, providing deep, unparalleled insight into the relation between the structure of the channel and its function. The three-dimensional solution of the various molecular domains allows a better understanding of the mechanisms that lead to gating alterations and from there, to the loss or gain of function that can act as substrate for an arrhythmic phenotype.

![The cardiac voltage-gated sodium channel Na~V~1.5. Upper panel: unfolded Na~V~1.5 protein at the cardiomyocyte plasma membrane featuring four domains (I, II, III, IV) each containing six segments (S1--S6). The charged segment S4 is represented in green. Lower left panel: folded Na~V~1.5 at the cardiomyocyte plasma membrane. The rapid inward sodium current depolarizes the cell membrane. Lower right panel: relation between the sodium current and the upstroke of the action potential (green segments).](cvaa082f1){#cvaa082-F1}

2.2. Sodium channel distribution and interacting proteins
---------------------------------------------------------

Na~V~1.5 expression levels vary throughout different regions of the heart, in line with regional differences in speed of conduction (*Figure [2](#cvaa082-F2){ref-type="fig"}*, left panel).[@cvaa082-B24]^,^[@cvaa082-B25] Although very lowly expressed in the central part of the slowly conducting sinus node, Na~V~1.5 expression is found in the periphery of the sinoatrial node, where its presence is required for proper sinus node function.[@cvaa082-B26] Na~V~1.5 is present at low levels in the inferior nodal extension (INE) and transitional zone of the atrioventricular (AV) ring, where conduction is slow.[@cvaa082-B29] However, Na~V~1.5 is not expressed in the compact atrioventricular node (AVN) and its absence is crucial for proper AV function by ensuring a delay between atrial and ventricular activation.[@cvaa082-B29]^,^[@cvaa082-B30]^,^[@cvaa082-B32] In contrast, Na~V~1.5 expression is prominent in the AV-bundle, His and Purkinje fibres where conduction is fastest (up to 2 m/s).[@cvaa082-B24]^,^[@cvaa082-B26] The sodium channel is furthermore broadly expressed in atrial and ventricular working myocardium.[@cvaa082-B26]^,^[@cvaa082-B33] In both ventricles, a transmural gradient is observed with higher expression of *SCN5A* and Na~V~1.5 in the subendocardium than in the subepicardium.[@cvaa082-B26]*SCN5A* and Na~V~1.5 are moreover expressed at lower levels in the right ventricular outflow tract as compared to the ventricles; nevertheless, in healthy myocardium, this does not lead to conduction slowing within this region.[@cvaa082-B34] Differential patterning of Na~V~1.5 also exists within subcellular microdomains of the cardiomyocyte (*Figure [2](#cvaa082-F2){ref-type="fig"}*, right panel). The combination of nanometre precision microscopy and patch-clamp techniques has shown that Na~V~1.5 channels gather at the membrane in clusters,[@cvaa082-B35] with biophysical properties of Na~V~1.5 clusters differing between cardiomyocyte microdomains. Indeed, sodium channels located at the intercalated disc (ID) generate larger currents than those located at the lateral membrane (LM).[@cvaa082-B36]^,^[@cvaa082-B37] In addition, gating properties also differ according to location with a positive shift in steady-state activation, a negative shift in steady-state inactivation, and a slower recovery from inactivation observed for channels located at the LM as compared to those at the ID.[@cvaa082-B36] In the latter, three additional distinct pools of Na~V~1.5 channels have been identified (sarcolemmal crests, grooves, and T-tubules), with crests carrying the largest currents and T-tubules the smallest.[@cvaa082-B35]^,^[@cvaa082-B38]^,^[@cvaa082-B39] Na~V~1.5 channels associate with partner proteins to form region-specific macromolecular complexes.[@cvaa082-B40] The large variety in interacting proteins already suggests that different macromolecular complexes may be relevant for specific functions at different locations and may be differentially regulated. Na~V~1.5 can be found, for example, in proximity to N-cadherin, connexin 43, plakophilin-2 (PKP2), ankyrin-G, βIV-spectrin, calcium/calmodulin-dependent protein kinase II (CaMKII), coxsackie and adeno virus receptor, zonula occludens 1, and synapse-associated protein 97 at the ID, whereas it associates mainly with the dystrophin--syntrophin complex at the LM.[@cvaa082-B40] Moreover, it has been suggested that of the accessory β-subunits (which modulate Na~V~1.5 channel density and kinetics[@cvaa082-B41]) β2 and β4 are located preferentially at the ID while β1 and β3 are localized mainly in the T-tubules.[@cvaa082-B42] The functional relevance of these distinct sodium channel complexes is exemplified by the fact that mutations in Na~V~1.5 interacting proteins are associated with various arrhythmia syndromes.[@cvaa082-B43] These observations furthermore shed light on potential microdomain-specific function of Na~V~1.5, as will be discussed in more detail below.

![Regional and subcellular distribution of *SCN5A*/Na~V~1.5 in the heart and cardiomyocyte. Left panel: schematic representation of a heart showing the expression level of *SCN5A* in the different compartments. Expression of *SCN5A* is highest in the AV bundle, His bundle, and RBB and LBB (dark green). *SCN5A* is broadly expressed in RA and LA and RV and LV with an epi/endo gradient in the ventricles. *SCN5A* is absent from the central SAN and AVN. Right panel: schematic representation of the localization of Na~V~1.5 with specific regional partner proteins in the microdomains of the cardiomyocyte: ID, LM, and T-tubules. The sodium current generated at the ID is larger than the sodium current generated at the LM. LA, left atria; LBB, left bundle branch; LV, left ventricle; RA, right atria; RBB, right bundle branch; RV, right ventricle; SAN, sinoatrial node.](cvaa082f2){#cvaa082-F2}

3. Inherited disorders associated with Na~V~1.5 dysfunction
===========================================================

Mutations in the *SCN5A* gene, leading to Na~V~1.5 dysfunction, have been linked to various types of cardiac electrical diseases. As discussed in more detail below, these syndromes each display distinct clinical and electrophysiological characteristics, despite the fact that they are caused by mutations in the same ion channel. From a biophysical point of view, these alterations may be divided into those leading to a loss or to a gain of Na~V~1.5 function (*Figure [3](#cvaa082-F3){ref-type="fig"}*). Loss of function mutations in *SCN5A* lead to decreased peak sodium current and conduction slowing. On the other hand, gain of function *SCN5A* mutations affecting (recovery from) inactivation are associated with increased late sodium current, leading to persistent sodium influx during the course of the action potential, thereby prolonging repolarization. In some cases, a single *SCN5A* mutation may cause at the same time gain and loss of function biophysical defects leading to an overlap phenotype (see below), and occasionally mutations are also associated with cardiac structural abnormalities.[@cvaa082-B4]^,^[@cvaa082-B5]^,^[@cvaa082-B45] This diversity in phenotypic expression furthermore underscores the importance of the diversity and multifunctionality of *SCN5A*/Na~V~1.5. We first describe briefly the main phenotypical characteristics of the various inherited syndromes associated with Na~V~1.5 dysfunction, before exploring in more detail the diverse actions of sodium channels in the next section.

![Schematic representation of the arrhythmogenic consequences of reduced peak sodium current (peak I~Na~; left) and increased late sodium current (late I~Na~; right). APD, action potential duration; \[Ca^2+^\]~i~, intracellular calcium concentration; \[Na^+^\]~i~, intracellular sodium concentration. Redrawn from Remme and Wilde[@cvaa082-B44] with permission.](cvaa082f3){#cvaa082-F3}

3.1. Long QT syndrome type 3
----------------------------

LQT3 is characterized by prolonged QT intervals on the electrocardiogram (ECG) and increased risk for sudden death due to ventricular tachyarrhythmias, in particular Torsades de Pointes. LQT3 patients often display bradycardia, and ventricular arrhythmias occur predominantly at slow heart rates, i.e. during rest.[@cvaa082-B46]^,^[@cvaa082-B47] Unfortunately, cardiac arrest (rather than syncope) is often the first clinical event.[@cvaa082-B46]^,^[@cvaa082-B48] The underlying biophysical alterations include action potential prolongation due to enhanced I~Na,L~, secondary to mutation-induced altered or incomplete Na~V~1.5 inactivation.[@cvaa082-B49]^,^[@cvaa082-B50] Management of LQT3 patients includes beta-blocker therapy, pacemaker implantation in selected cases, and implantable cardioverter-defibrillator (ICD) implantation in patients at high risk of arrhythmias. Additional strategies aimed at inhibiting I~Na,L~ are currently under investigation.[@cvaa082-B51]

3.2. Brugada syndrome
---------------------

BrS is characterized by ST-segment elevation in the right-precordial leads on the ECG, which may be variably present but unmasked or increased by Class 1A or 1C anti-arrhythmic sodium channel blocking drugs (ajmaline, flecainide). BrS has an increased prevalence in males and is associated with an increased risk for ventricular arrhythmias and sudden death occurring mostly during rest or sleep.[@cvaa082-B52] In approximately 20% of BrS patients, *SCN5A* mutations are identified, which are typically 'loss-of-function' mutations leading to reduced sodium channel availability.[@cvaa082-B53]^,^[@cvaa082-B54] Mechanisms involved in BrS include conduction abnormalities, increased (transmural) heterogeneity in action potential duration and right ventricular structural abnormalities.[@cvaa082-B55] Management options include ICD implantation and measures aimed at preventing known arrhythmia-provoking factors such as fever; quinidine may be added as an adjunct therapy to decrease the incidence of ventricular arrhythmias.[@cvaa082-B56]

3.3. Progressive cardiac conduction defect and sick sinus syndrome
------------------------------------------------------------------

Loss-of-function mutations in *SCN5A* leading to reduced sodium channel availability have been associated with inherited sick sinus syndrome and progressive cardiac conduction defect (PCCD).[@cvaa082-B57] PCCD, also called Lenègre or Lev disease, is characterized by progressive conduction slowing through the His--Purkinje system, with right and/or left bundle branch block and QRS-widening, leading to complete AV block, syncope, and sudden death.

3.4. Atrial fibrillation
------------------------

In addition to acquired, age-related conditions, AF may also occur as a hereditary disease in young patients with structurally normal hearts. Both loss of function and gain of function mutations in *SCN5A* have been associated with familial AF, which may induce AF through decreased atrial conduction velocity and increased atrial action potential duration and excitability, respectively.[@cvaa082-B60]^,^[@cvaa082-B61]

3.5. Dilated cardiomyopathy
---------------------------

In rare cases (1.7%[@cvaa082-B62]) *SCN5A* mutations are also associated with DCM,[@cvaa082-B3] often presenting in combination with atrial arrhythmias and/or fibrillation.[@cvaa082-B7] Recently a common polymorphism in *SCN5A* (rs1805124) has been associated with the development of DCM.[@cvaa082-B63]*SCN5A* mutations leading to DCM have been associated with both loss and gain of sodium channel function.[@cvaa082-B64] The mechanisms underlying DCM secondary to *SCN5A* mutations are likely complex, involving altered (late) sodium current or proton leak current (pre-existent) myocardial structural abnormalities, and the presence of long-standing (atrial) arrhythmias.[@cvaa082-B66]^,^[@cvaa082-B67]

3.6. Sodium channel overlap syndrome
------------------------------------

A single *SCN5A* mutation may also result in multiple disease phenotypes, referred to as 'sodium channel overlap syndrome'. For example, the *SCN5A*-1795insD mutation is associated with sinus node dysfunction, bradycardia, conduction disease, BrS, and LQT3 in a large Dutch family with a high risk for nocturnal sudden death.[@cvaa082-B11]^,^[@cvaa082-B68] The simultaneous presence of LQT3 (i.e. gain of function) and BrS or conduction disease (i.e. loss of function) due to one single *SCN5A* mutation may seem unlikely given the apparent opposing biophysical alterations underlying both clinical entities. However, studies by us and others have shown that *SCN5A*-1795insD as well as the overlap mutations *SCN5A*-E1784K and *SCN5A*-delK1500 reduce peak current density while simultaneously increasing I~Na,L~ magnitude, providing the biophysical basis for the clinical overlap syndrome phenotype.[@cvaa082-B69]

3.7. Arrhythmogenic cardiomyopathy/ARVC
---------------------------------------

Inherited arrhythmogenic cardiomyopathy (ACM), previously designated ARVC is associated with cardiomyopathic changes, heart failure, ventricular arrhythmias, and sudden death. Mutations in desmosomal proteins are identified in most affected individuals, including plakoglobin, PKP2, and desmoglein-2.[@cvaa082-B72] A number of these desmosomal proteins have been shown to interact with Na~V~1.5 and as a consequence, reduced I~Na~ is a common feature in ACM/ARVC disease models.[@cvaa082-B9]^,^[@cvaa082-B73]^,^[@cvaa082-B74] More recently, rare variants in *SCN5A* have been identified in ACM/ARVC patients.[@cvaa082-B8]^,^[@cvaa082-B75] For one of these mutations, studies in human-induced pluripotent stem cells-derived cardiomyocytes demonstrated a reduction in I~Na~ and a potential detrimental effect on cell adhesion, potentially (partly) explaining the observed ACM phenotype.[@cvaa082-B8]

4. Multifunctionality of Na~V~1.5
=================================

The diversity in electrical and structural phenotypes secondary to *SCN5A* mutations described in the previous section may be considered unexpected and disputes the idea that the sole role of the cardiac sodium channel lies in the initiation and propagation of the cardiac action potential. Indeed, aided by advanced imaging and electrophysiological techniques, studies in the last decade have revealed an increasing diversity and complexity of sodium channels in the heart and the cardiomyocyte. In this section, we explore in more detail the diverse ionic and non-ionic mechanisms by which sodium channel (dys)function leads to electrical and structural alterations.

4.1 Direct ionic (dys)function of Na~V~1.5
------------------------------------------

### 4.1.1. Direct ionic consequences of inherited Na~V~1.5 (dys)function

Clearly, the ion-conducting role of Na~V~1.5 is essential for cardiac electrical function, with alterations in sodium ion influx, i.e. through loss of function or gain of function of Na~V~1.5, directly impacting on either depolarization or repolarization characteristics of the cardiomyocyte. In inherited arrhythmia syndromes, loss of function mutations in *SCN5A* can lead to a decreased number of functional channels on the membrane due to misfolding of the channel and/or altered trafficking.[@cvaa082-B53]^,^[@cvaa082-B54]^,^[@cvaa082-B76] Sodium current magnitude may also be decreased secondary to reduced conductivity or a shift in the voltage dependence of (in)activation. Similar alterations in sodium channel trafficking and/or kinetics may also occur as a consequence of alterations in proteins interacting with Na~V~1.5. In all situations, reduced sodium channel availability leads to decreased cardiac excitability and pro-arrhythmic conduction slowing. Gain of function *SCN5A* mutations may lead to enhanced late sodium current through a number of potential mechanisms: (i) disruption of fast inactivation, thereby allowing for sodium channels to re-open,[@cvaa082-B49] (ii) incomplete or slowed inactivation, resulting in channel openings of longer duration, and (iii) a shift in voltage dependence of inactivation with a consequent increased voltage range of incomplete current inactivation (resulting in an increase in window current). In addition, faster recovery from inactivation (causing increased sodium channel availability), or increased peak I~Na~ density may occur.[@cvaa082-B50]^,^[@cvaa082-B77]^,^[@cvaa082-B78] Finally, enhanced I~Na,L~ has also been observed secondary to mutations in proteins interacting with Na~V~1.5. Independent of the underlying mechanism, the consequence is an enhanced and prolonged sodium influx during the action potential resulting in delayed repolarization, action potential prolongation, and early afterdepolarizations which may subsequently trigger Torsades de Pointes arrhythmias and sudden death. These direct ionic mechanisms underlying Na~v~1.5 dysfunction appear straightforward, but it must be remembered that the biophysical effects of *SCN5A* mutations are usually investigated in heterologous expression systems which may not adequately reflect the cardiomyocyte environment.[@cvaa082-B79] Indeed, the actual situation in the heart is likely more complex due to transcriptional and post-translational regulation, and Na~V~1.5 complex diversity within subcellular microdomains.

### 4.1.2. Modulation of the direct ionic effect of Na~V~1.5

Splicing of *SCN5A* is age- and species-dependent and leads to transcript variants with different functional characteristics, including peak and late sodium current magnitude.[@cvaa082-B80]^,^[@cvaa082-B81] Alternative splicing of *SCN5A* may be of significant functional relevance for disease expressivity in sodium channelopathy. For instance, the *SCN5A*-L409P mutation leads to more severe biophysical defects in the presence of the neonatal isoform, including an increased I~Na,L~, potentially explaining the unusual severity and early onset of long QT syndrome in the affected foetus.[@cvaa082-B82] In addition, splice variants have been shown to differentially modulate the reduced sodium channel membrane expression consequent to the BrS mutation *SCN5A*-G1406R.[@cvaa082-B83] Post-translationally, Na~V~1.5 is predominantly regulated by phosphorylation, ubiquitylation, and glycosylation (reviewed in[@cvaa082-B84]^,^[@cvaa082-B85]). While glycosylation may affect sodium channel gating,[@cvaa082-B84]^,^[@cvaa082-B86] ubiquitylation is mainly responsible for regulating the number of plasma membrane proteins at the cell surface by subjecting Na~V~1.5 to proteosomal or lysosomal degradation.[@cvaa082-B87] Na~V~1.5 trafficking and the density of channels at the membrane has furthermore been shown to be regulated by a large variety of mechanisms including protein kinases A and C, CaMKII,[@cvaa082-B85] reactive oxygen species (ROS),[@cvaa082-B88] intracellular calcium levels,[@cvaa082-B89] temperature,[@cvaa082-B90] extracellular protons and pH,[@cvaa082-B91] and stretch.[@cvaa082-B92] Hence, various modulatory mechanisms may alter the ion-conducting properties of Na~V~1.5, thereby directly impacting on cardiac excitability and/or repolarization, and consequent arrhythmogenesis.

### 4.1.3. Direct ionic (dys)function of Na~V~1.5 in microdomains

As described above, Na~V~1.5 channels are not randomly distributed along the cardiomyocyte membrane but are regionally organized in clusters and macromolecular complexes. The differences in Na~V~1.5 expression, sodium current density and kinetics observed between these subcellular microdomains (i.e. ID vs. LM), may be explained at least in part by the regional variation in modulatory Na~V~1.5 interacting proteins. Hence, mutations in *SCN5A* or in genes coding for Na~V~1.5 partner proteins may not only affect ionic Na~V~1.5 function, but in fact may do so in a microdomain-specific manner. Sodium channels located at the LM are associated with the syntrophin--dystrophin complex, and dystrophin-deficient mdx mice display reduced Na~V~1.5 expression levels predominantly at the LM.[@cvaa082-B93] Na~V~1.5 channels lacking the three last amino acids at the C-terminal domain (ΔSIV) no longer interact with alpha-1-syntrophin and *Scn5a*-ΔSIV mice display reduced sodium current specifically at the LM, where syntrophin is exclusively located.[@cvaa082-B94] This LM-specific decrease in sodium current resulted in reduced transversal conduction velocity and PR- and QRS-prolongation in *Scn5a*-ΔSIV mice. The A257G-*SNTA1* mutation in alpha-1-syntrophin on the other hand causes a gain of function of Na~V~1.5 as seen in LQTS.[@cvaa082-B95] Similarly, a mutation in caveolin-3, another LM partner of Na~V~1.5, causes a gain-of-function of Na~V~1.5 and LQTS in patients.[@cvaa082-B96] The impact of these mutations on the subcellular ionic function of Na~V~1.5 has not been assessed; however, since both alpha-1-syntrophin and caveolin-3 are both LM partner proteins of Na~V~1.5, one may speculate that the observed gain of function is mediated specifically by LM-based Na~V~1.5 channels. In contrast, alterations in Na~V~1.5 partner proteins at the ID have mostly resulted in loss of sodium channel function in this microdomain and consequently conduction slowing and arrhythmias. For instance, the *Gja1*-D378stop mutation in Cx43 was associated with lethal arrhythmic events in mice and reduced sodium current at the ID due to trafficking defects.[@cvaa082-B97]^,^[@cvaa082-B98] In addition, heterozygous deletion of the coxsackie and adeno virus receptor resulted in loss-of-function of the sodium channel specifically at the ID and enhanced arrhythmia susceptibility during myocardial infarction in both humans and mice.[@cvaa082-B37] Moreover, mutations in the desmosomal proteins plakophilin 2, desmoglein 2, and plakoglobin lead to ACM/ARVC, decreased Na~V~1.5 current at the ID region and consequent conduction slowing and pro-arrhythmia.[@cvaa082-B9]^,^[@cvaa082-B10]^,^[@cvaa082-B73] Patients harbouring mutations in sodium channel β subunit genes display a diversity of arrhythmic syndromes similar to *SCN5A* channelopathies, including BrS and/or CCD (β1 and β3), LQTS (β4), AF (β1, β2, and β3), and idiopathic ventricular fibrillation (β3).[@cvaa082-B99] While preferential localization of certain β subunits at the ID (β2 and β4) vs. T-tubules (β1 and β3) has been suggested,[@cvaa082-B42] any microdomain-specific alterations in Na~V~1.5 function secondary to these mutations remain to be elucidated.[@cvaa082-B99] Similarly, mutations in *GPDL1* and *MOG1* encoding the probable glycerophosphoryl diester phosphodiesterase 1 and the nucleocytoplasmic transport protein multicopy suppressor of Gsp1, respectively, have been linked to BrS and reduced sodium current, but their distinct subcellular consequences remain as yet unknown.[@cvaa082-B104] Overall, these studies have provided some additional insight into the ionic function of Na~V~1.5 within distinct microdomains. It may be tempting to speculate that Na~V~1.5-dysfunction primarily affects conduction at the ID and ionic homeostasis mostly at the LM, or loss-of-function *SCN5A* mutations predominantly impact the ID and gain of function mutations mostly the LM. However, further investigations are necessary to fully elucidate the potential microdomain-specific effects and consequences of mutations in *SCN5A* and Na~V~1.5 partner proteins.

4.2 Indirect ionic effects of Na~V~1.5 (dys)function
----------------------------------------------------

Indirect ionic effects of cardiac sodium channels are related to mechanisms or pathways that are activated by the alterations in intracellular sodium concentration consequent to the influx of sodium ions through Na~V~1.5 into the cardiomyocyte. In addition to implications for (pro-arrhythmic) alterations in intracellular calcium concentrations, other consequences include metabolic dysregulation and activation of calcium-dependent signalling pathways. Here, essential insight may also be gained from findings in cell types other than cardiomyocytes.

### 4.2.1. Na~V~1.5 dysfunction and dysregulation of intracellular sodium--calcium homeostasis

The most established indirect ionic action of Na~V~1.5 is its secondary effect on intracellular sodium--calcium homeostasis. The increase in intracellular Na^+^ concentration (\[Na^+^\]~i~) following opening of Na~V~1.5 channels induces membrane depolarization which facilitates opening of L-type calcium channels and subsequent calcium-induced calcium release from the sarcoplasmic reticulum (SR). As a consequence, the cytosolic Ca^2+^ concentration (\[Ca^2+^\]~i~) increases which is essential for excitation--contraction coupling. Following the upstroke of the action potential Na^+^ ions will be pumped out of the cell by the Na^+^/Ca^2+^-exchanger (NCX) acting in reverse mode exchanging 3 Na^+^ for 1 Ca^2+^. Rise in cytosolic Ca^2+^ concentration (\[Ca^2+^\]~i~) due to Ca^2+^ release from the SR will force the NCX in the forward mode pumping 1 Ca^2+^ out and 3 Na^+^ in the cell. The \[Na^+^\]~i~ will return to its normal level in diastole due to activity of the sodium potassium pump, Na^+^/K^+^-ATPase, which exchanges 3 Na^+^ ions for 2 K^+^. Any condition leading to increased diastolic \[Na^+^\]~i~ will in turn, enhance reverse mode activity of the NCX, consequently resulting in increased diastolic \[Ca^2+^\]~i~.[@cvaa082-B107] Indeed, enhanced I~Na,L~ in the setting of gain of function *SCN5A* mutations or heart failure has been shown to increase both \[Na^+^\]~i~ and \[Ca^2+^\]~i~ in ventricular cardiomyocytes.[@cvaa082-B108]^,^[@cvaa082-B109] Deletion of the Na~V~1.5 accessory subunit β1 also led to increase in tetrodotoxin (TTX)-sensitive sodium current and disrupted calcium homeostasis.[@cvaa082-B110] Transcriptional regulation of calcium-handling genes was observed in *Scn5a-N1325S* mice,[@cvaa082-B111] suggesting a link between sodium channel activity and calcium-dependent transcriptional pathways. Moreover, elevated diastolic \[Ca^2+^\]~i~ affects gene expression by activation of signalling pathways (discussed in the next paragraph) but also increases SR Ca^2+^ concentration (\[Ca^2+^\]~SR~). Both elevated \[Ca^2+^\]~i~ and \[Ca^2+^\]~SR~ increase the open probability of the ryanodine receptors causing calcium aftertransients leading to delayed afterdepolarizations, which may trigger an action potential and initiate arrhythmias. Elevated diastolic \[Ca^2+^\]~i~ may also impair cardiomyocyte relaxation, leading to diastolic dysfunction, and additionally decrease L-type Ca^2+^ current. Interestingly, high Ca^2+^ concentrations have been shown to prolong AV-conduction in isolated rabbit hearts.[@cvaa082-B112] Hence, it may be speculated that elevated diastolic \[Ca^2+^\]~i~ reduces L-type Ca^2+^ current in transitional cells surrounding the sinus node and AVN (where *SCN5A* and Na~V~1.5 are present at low levels), thereby affecting action potential upstroke and contributing to the phenotype of the bradycardia and prolonged PR interval often observed in patients with *SCN5A* mutations.[@cvaa082-B11]^,^[@cvaa082-B71] Thus, these indirect, ionic effects of Na~V~1.5 dysfunction acting through Na^+^ and Ca^2+^ homeostasis have important consequences for AV-conduction, pro-arrhythmia, and possibly mechanical dysfunction (see Section 5). In addition, DCM-related mutations (such as *SCN5A*-R219H) have been shown to cause a proton leak current, suggesting that intracellular acidification may contribute to the cardiomyopathy (and arrhythmias) observed in mutation carriers.[@cvaa082-B67]

### 4.2.2. Effects of Na~V~1.5 (dys)function on calcium-dependent signalling pathways

While increased \[Ca^2+^\]~i~ is detrimental to the contractile function of myocytes and the development of arrhythmias, enhanced calcium signalling can also have unfavourable consequences in the long run. General or local increases in \[Ca^2+^\]~i~ in the cardiomyocyte are predominantly sensed by calmodulin, a ubiquitous calcium sensor. Ca^2+^-calmodulin can activate, for example, CaMKII and protein phosphatase calcineurin (CaN). Both the CaMKII and the CaN signalling pathways control gene transcription leading to the development of cardiac hypertrophy and fibrosis, via histone deacetylases and the nuclear factor of activated T cells, respectively, and this process is referred to as 'excitation--transcription coupling'.[@cvaa082-B113]^,^[@cvaa082-B114] Both CaMKII and CaN pathways are activated in heart failure due to elevated \[Ca^2+^\]~i~. The cause of elevated diastolic \[Ca^2+^\]~i~ in heart failure is multifactorial and may involve I~Na~, I~CaL~, NCX, SR Ca-ATPase, ryanodine receptors, and other factors.[@cvaa082-B115] In this setting, the indirect ionic effect of the sodium channel may be mediated by I~Na,L~ which is increased in heart failure.[@cvaa082-B22]^,^[@cvaa082-B116] Calcium-activated CaMKII may in turn feedback on the sodium channel and regulate its (in)direct functions as has been shown in the setting of heart failure.[@cvaa082-B117]^,^[@cvaa082-B118] CaMKII phosphorylates Na~V~1.5 at several residues in the DI-DII loop,[@cvaa082-B119] and CaMKII-mediated phosphorylation of Na~V~1.5 at Ser571 increases I~Na,L~.[@cvaa082-B120] On the other hand, phosphorylation of the Thr594 and Ser516 residues lead to a loss of function phenotype as seen in BrS.[@cvaa082-B121] The C-terminus of Na~V~1.5 harbours an EF-hand Ca^2+^ binding site. The EF-hand interacts with the IQ motif \[binding site for calmodulin (CaM)\] and the DIII--DIV linker to control inactivation of the channel.[@cvaa082-B122]^,^[@cvaa082-B123] Therefore, increases in \[Ca^2+^\]~i~ may not only activate calcium-dependent (pro-hypertrophic) signalling pathways, but also directly feedback on Na~V~1.5 either directly or via CaM/CaMKII and contribute to arrhythmogenesis. Finally, dysregulated intracellular Na^+^ and Ca^2+^ homeostasis may also affect mitochondrial (dys)function,[@cvaa082-B124] potentially leading to pro-arrhythmic ROS production.[@cvaa082-B125]

### 4.2.3. Evidence from cells other than cardiomyocytes

Sodium and calcium signalling pathways have much broader targets than the ones described above and interest in sodium channels in non-excitable cells has yielded precious information on other indirect ionic functions of the sodium channel. Na~V~1.5 channels are also expressed in non-excitable cells where they participate in diverse cell functions.[@cvaa082-B126] In CD4^+^ CD8^+^ double positive (DP) thymocytes, stage-specific expression of *SCN5A* controls positive selection (maturation of thymocytes into T cells).[@cvaa082-B127] TTX treatment or shRNA knockdown prevented positive selection of DP thymocytes, by decreasing the secondary sustained Ca^2+^ flux. Indirect ionic functions of sodium channels can also be achieved when not expressed at the plasma membrane. Na~V~1.5 is located intracellularly at the membrane of late endosomes in human monocyte-derived macrophages.[@cvaa082-B128] Phagocytosis was inhibited by 10 µM TTX in these cells which blocked the sodium current generated by Na~V~1.5 controlling acidification of late endosomes during this process.[@cvaa082-B128] Sodium channels are furthermore known to play a crucial role in tumour activity and metastasis, with Na~V~1.5 being most relevant in breast cancer, colon cancer, and ovary cancer.[@cvaa082-B126] Increased expression of Na~V~1.5 in these tumours is associated with more aggressive properties, including invasion of the lymph nodes and recurrence of metastasis.[@cvaa082-B129]^,^[@cvaa082-B130] Indirect ionic mechanisms of Na~V~1.5 are thought to be involved in this process.[@cvaa082-B129] Increased I~Na~, through its effect on the sodium--hydrogen exchanger, induces acidification of the extracellular environment, which increases cathepsin activity, invadopodial formation, and extracellular matrix degeneration, and thus facilitates tumour invasion.[@cvaa082-B129]^,^[@cvaa082-B131] Another mechanism by which altered Na~V~1.5 function may affect tumour behaviour is through its effects on calcium-dependent SNARE-mediated vesicle fusion. Here, increased \[Ca^2+^\]~i~ levels (secondary to enhanced I~Na,L~) may stimulate podosome activity and increase motility of the tumour cell, thus contributing to cellular invasion.[@cvaa082-B129]^,^[@cvaa082-B132] Indeed, in MDA-MB-231 breast cancer cells, Na~V~1.5 was shown to generate an I~Na,L~ that could be inhibited by 30 µM TTX.[@cvaa082-B130] Reduction of either the peak or late sodium current decreased invasiveness of cancer cells, while increasing I~Na,L~ promoted it. Other studies have confirmed the beneficial effects of (late) sodium current inhibition on tumour growth, invasion, proliferation, and metastasis.[@cvaa082-B133]^,^[@cvaa082-B134] These observations clearly demonstrate that voltage-gated sodium channels are capable of controlling diverse cell functions in non-excitable cells such as activation of calcium signalling pathways and local acidification. Mechanistic insight drawn from these studies may facilitate further exploration of indirect ionic effects of Na~V~1.5 in cardiomyocytes.

4.3 Non-ionic effects of Na~V~1.5 (dys)function
-----------------------------------------------

### 4.3.1. Non-ionic function of Na~V~1.5 during cardiac development

Non-ionic functions of cardiac sodium channels are related to effects mediated by the Na~V~1.5 protein itself or the protein complexes it is associated with, independent of the influx of sodium ions through the channel pore. Evidence for such non-ionic function of Na~V~1.5 in the heart was first demonstrated during cardiac development. Na~V~1.5 is expressed from embryonic day 9.5 (ED9.5) onward in the working myocardium of the murine embryonic ventricle.[@cvaa082-B135] Mice with homozygous deficiency of Na~V~1.5 die *in utero* around ED9.5 showing ventricular malformation including absence of trabeculae.[@cvaa082-B71]^,^[@cvaa082-B135]^,^[@cvaa082-B136] Whether ionic and/or non-ionic functions of Na~V~1.5 are involved here is as yet unclear. However, one could speculate that a role for direct ionic actions of Na~V~1.5 is less likely since cardiomyocyte membrane potentials during early development are relatively depolarized, leaving Na~V~1.5-based channels mostly inactivated and cardiac electrical activity driven predominantly by calcium channels.[@cvaa082-B137] A key study in zebrafish embryos showed that knockdown of *Scn5a* led to decreased expression of the myocardial precursor genes *Nkx2-5*, *Gata4*, and *Hand2*, resulting in impaired cardiac development and cardiomyocyte proliferation. Crucially, abnormalities in cardiac development only occurred when the Na~V~1.5 protein was absent but not when I~Na~ was pharmacologically inhibited, indicating that the direct ionic function of Na~V~1.5 was not involved.[@cvaa082-B138] Although these data clearly point to a role for non-ionic function of Na~V~1.5 in ventricular malformation and embryonic death, the underlying mechanism requires further investigation, in addition to the potential relevance of the embryonic *Scn5a* isoform in this process.

### 4.3.2. Actions of Na~V~1.5 through its macromolecular complex

As described above, Na~V~1.5 forms part of a macromolecular complex where it interacts with a variety of other proteins. While it is clear that these interacting proteins modulate Na~V~1.5 function, it is as yet unknown if the opposite is also true, i.e. whether Na~V~1.5 (dys)function also impacts on other components of the macromolecular complex. Through this complex, Na~V~1.5 may directly or indirectly interact with numerous proteins involved in cytoskeletal anchoring, signal transduction, and cell adhesion, including dystrophin, laminin, integrins, and components of the extracellular matrix. For example, Na~V~1.5 binds to fibroblast growth factor homologous factor (FHF); since the latter has been shown to interact with Cx43[@cvaa082-B139] (located at the ID) and with the L-type calcium channel[@cvaa082-B140] (located at the T-tubules in the LM), one could speculate that mutation-induced alterations in Na~V~1.5-FHF binding could lead to various (non-)ionic consequences, which may be microdomain-dependent.[@cvaa082-B141] The recently demonstrated interaction and co-regulation of Na~V~1.5 and potassium channels provides additional pathways by which Na~V~1.5 can indirectly affect cardiomyocyte (electrical) function.[@cvaa082-B142]^,^[@cvaa082-B143] It is not yet clear whether Na~V~1.5 dysfunction disrupts stability of the macromolecular complexes, thereby potentially affecting cell structure and integrity. If so, the consequences could be numerous and diverse, including alterations in mechanical function and development of cardiac structural abnormalities. Importantly, given the fact that the composition of the macromolecular complex differs between LM and ID, such non-ionic effects of Na~V~1.5 are likely subdomain-specific. During heart failure, for example, Na~V~1.5 is differentially regulated in the different cardiomyocyte microdomains.[@cvaa082-B144] Hence, Na~V~1.5 dysfunction could theoretically lead to disruption of the dystrophin--syntrophin complex and caveolin-3 at the LM, and of desmosomal proteins and connexins at the ID. Indeed, evidence is emerging which points towards a secondary effect of Na~V~1.5 dysfunction on ID remodelling.

### 4.3.3. Non-ionic function of Na~V~1.5 at the ID

Strong evidence for a non-ionic action of Na~V~1.5 comes from its function at the ID, where it has a potential role in cell adhesion. A large body of work identifies Na~V~1.5 as part of a larger complex at the ID, including N-cadherin, PKP2, β1, and connexin 43 clustered together and regulating each other to keep the integrity of cell--cell communication.[@cvaa082-B8]^,^[@cvaa082-B145]^,^[@cvaa082-B146] Loss of Na~V~1.5 has been shown to compromise the size and density of N-cadherin clusters at the ID membrane thereby altering adhesion of neighbouring cardiomyocytes, which, in turn, reduces peak I~Na~.[@cvaa082-B35] N-cadherin clusters are anchoring points for the microtubule network.[@cvaa082-B9]^,^[@cvaa082-B147] Hence, by indirectly altering N-cadherin integrity at the ID, sodium channel deficiency may disturb trafficking of molecules along microtubules to the ID. Evidence for a role of Na~V~1.5 in cell adhesion is further demonstrated by studies in ACM patients and mouse models of ACM. First, it has been shown that PKP2-heterozygous mice show decreased sodium current and a widening of the inter-cellular space at the ID.[@cvaa082-B10] This was seconded by the observation that many human variants in *PKP2* lead to reduced sodium current.[@cvaa082-B9] Finally, in a recent study the *SCN5A*-R1898H variant was identified in an ARVC patient. *In vitro* analysis of the consequences of the mutation showed reduced abundance of Na~V~1.5 (and reduced sodium current) and N-cadherin at the ID thereby compromising cell adhesion.[@cvaa082-B8] Na~V~1.5 has been identified in an additional signalling ID complex including ankyrin-G, β~IV~-spectrin, and CaMKII.[@cvaa082-B148] Further studies in neurons have shown that ankyrin-G is essential for clustering sodium channels at the membrane where they exert their function.[@cvaa082-B149] Thus, non-ionic effects of Na~V~1.5 dysfunction not only modulate electrophysiological properties of the myocardium, but may also affect cardiac structure and integrity, thereby further predisposing to arrhythmias. From these observations, one may argue that clinical management of sodium channelopathies may benefit from targeting not only Na~V~1.5, but also other components of its macromolecular complex.

### 4.3.4. Non-ionic function of Na~V~1.5 in non-excitable cells

As indicated above, increased expression of Na~V~1.5 in tumours is associated with more aggressive properties, including tissue invasion and metastasis.[@cvaa082-B126]^,^[@cvaa082-B131] In addition to pro-metastatic pathways induced by alterations in intracellular calcium homeostasis, non-ionic mechanisms may also be involved but remain as yet unexplored. Through its interaction with both cytoskeletal and ID proteins, alterations in Na~V~1.5 may impact on (intracellular) communication, cell organization, and morphology. A similar role in tumour invasion has already been demonstrated for the accessory β subunits, which additionally function as cell adhesion molecules. In particular, β1 expression in tumour cells has been shown to modulate their capacity for adhesion, migration, and invasion, while effects on angiogenesis have also been reported.[@cvaa082-B150] A functional role for Na~V~1.5 in gastrointestinal function has also been demonstrated, and *SCN5A* mutations have been linked to gut motility disorders such as irritable bowel syndrome.[@cvaa082-B151] Although alterations in excitability likely play a crucial role in mediating smooth muscle cell motility, it would be interesting to see whether non-ionic mechanisms are also involved.

5. (Non-)ionic consequences of Na~V~1.5 dysfunction: clinical and therapeutic considerations
============================================================================================

The majority of disease characteristics associated with Na~V~1.5 dysfunction are clearly the consequence of the electrophysiological defects of the channel leading to conduction slowing, repolarization abnormalities, and consequent arrhythmias. However, it is now increasingly recognized that *SCN5A* mutations may also lead to the development of cardiac fibrosis, dilatation, and hypertrophy, which cannot be readily explained by the sole electrical malfunction of Na~V~1.5 and that these diverse disease entities may co-exist with electrical abnormalities.[@cvaa082-B6]^,^[@cvaa082-B7] BrS patients carrying loss of function *SCN5A* mutations may suffer myocardium remodelling including right ventricular hypertrophy, fibrosis, epicardial fatty infiltration, and myocyte cytoplasm degeneration.[@cvaa082-B4]^,^[@cvaa082-B5] As mentioned in Section 2, DCM has been observed in patients with *SCN5A* mutations,[@cvaa082-B3] often in combination with AF.[@cvaa082-B7] Strikingly, there appears to be an age-dependent development of disease severity suggesting that structural changes develop secondary to sodium channel dysfunction and might manifest later in life. Slow and gradual development of structural abnormalities within the myocardium will influence the genesis and severity of arrhythmias. This could explain in part why the onset of disease is relatively late (mid 30s--40s) in patients carrying *SCN5A* mutations linked to BrS.[@cvaa082-B152] These observations are seconded by results obtained from mouse studies. In mice heterozygous for *Scn5a* (*Scn5a*^+/−^), cardiac fibrosis developed with age, and the occurrence and severity of ventricular arrhythmias correlated with the extent of structural abnormalities developed in the myocardium with ageing.[@cvaa082-B153]^,^[@cvaa082-B154] In the *Scn5a^1798insD/+^* mouse model, arrhythmic events and sudden cardiac death were more frequent with age and development of cardiac hypertrophy.[@cvaa082-B155] In addition, mice overexpressing the LQTS mutation *Scn5a-N1325S* developed extensive myocardial fibrosis at relatively advanced age (6--10 months) as well as loss of cardiomyocytes due to apoptosis.[@cvaa082-B156] Although it is not completely clear how a mutation in *SCN5A* leads to structural changes in the myocardium, we have here proposed a number of mechanisms, involving both (in)direct ionic and non-ionic roles of Na~V~1.5*.* In the case of loss of function, as seen in ARVC/ACM, the physical disassociation of Na~V~1.5 from structural proteins may create structural abnormalities, indicating a role for non-ionic actions of Na~V~1.5. In the case of gain of function mutations in *SCN5A* or acquired diseases leading to enhanced I~Na,L~, increases in intracellular calcium may, in addition to providing an arrhythmic substrate, activate calcium-dependent signalling pathways and lead to the development of fibrosis.[@cvaa082-B108]^,^[@cvaa082-B109]

In addition to the potential mechanisms described above, electrical activity-dependent stimulation of pro-fibrotic factors of the transforming growth factor β pathway has been described in the setting of sodium channel dysfunction.[@cvaa082-B157] Moreover, *de novo* expression of Na~V~1.5 in myofibroblasts could contribute to direct ionic function by coupling myofibroblasts to cardiomyocytes, but also to an indirect ionic effect by activating fibrotic signalling pathways.[@cvaa082-B158] Irrespective of the underlying mechanisms, i.e. gain or loss of function, and ionic vs. non-ionic, development of structural cardiac abnormalities may increase the likelihood of arrhythmias by itself, and by acting in concert with the electrophysiological alterations induced by the mutation. Overall, these subtle structural abnormalities are generally not detectable on non-invasive examinations, which render the correlation with indirect ionic and non-ionic effects of Na~V~1.5 dysfunction challenging. However, an echocardiography study in *SCN5A*-1795insD mutation carriers revealed ventricular diastolic dysfunction in a number of patients, confirming the potential clinical relevance and opportunities for continued monitoring of ventricular function and identification of structural changes during follow-up.[@cvaa082-B45] Crucially, this may also allow the detection of potential switches in arrhythmogenic substrate from a direct ionic to indirect or non-ionic effects with age. Here, it is important to realize that co-development of structural changes commonly observed in older individuals, such as fibrosis and cardiac hypertrophy secondary to hypertension may further increase arrhythmia risk in *SCN5A* mutation carriers.[@cvaa082-B155] Similarly, the presence of co-morbidities associated with calcium abnormalities, enhanced late sodium current, metabolic dysregulation, and increased mitochondrial ROS production (e.g. heart failure, diabetes mellitus, obesity)[@cvaa082-B159]^,^[@cvaa082-B160] may further enhance calcium-dependent pro-arrhythmic events, particularly in the setting of gain of function *SCN5A* mutation. Clearly, these considerations may have significant consequences for disease outcome and patient management, making it essential to further unravel the ionic and non-ionic indirect consequences of Na~V~1.5 dysfunction.

As yet, therapeutic options for patients with *SCN5A* mutations are limited. In some cases, loss of sodium channel function may be targeted by certain sodium channel blockers (for instance mexiletine) which can restore membrane expression of trafficking defective sodium channels.[@cvaa082-B161] This, however, does not constitute an attractive therapeutic approach for clinical practice due to the potential deleterious effects of I~Na~ reduction. Other approaches to safely enhance Na~V~1.5 trafficking and/or function are currently under investigation. Meanwhile, options to prevent the detrimental consequences of loss of Na~V~1.5 function may be further explored, including for instance anti-fibrotic therapy. In the case of gain of function *SCN5A* mutations, current therapy is predominantly aimed at preventing arrhythmia triggers (e.g. beta-blockade, pacemaker implantation), although pharmacological I~Na,L~ inhibition is increasingly recognized as an attractive therapeutic target.[@cvaa082-B51]^,^[@cvaa082-B162] In addition to normalizing repolarization, I~Na,L~ inhibition may also be beneficial by restoring pro-arrhythmic intracellular calcium dysregulation, decreasing diastolic dysfunction, and preventing activation of calcium-dependent pro-hypertrophic signalling pathways.[@cvaa082-B109]^,^[@cvaa082-B155]^,^[@cvaa082-B163] Therapies aimed at improving cardiomyocyte metabolism and mitochondrial function (e.g. ROS scavengers) may also prove of benefit in these patients. Thus, preventing the development of cardiac structural defects and metabolic derangements may prove a valuable way of reducing risk for arrhythmias and sudden cardiac death in patients with sodium channel dysfunction.

6. Conclusions
==============

In the past two decades, clinical and genetic research combined with basic studies employing patch-clamp and nanometre precision techniques have enabled colossal advances in our understanding of sodium channel (dys)function. These investigations have provided insight into the relation between the structure of the channel, the structure of the channel interacting with its protein partners, and the effects of mutations on its function. More recently, studies have focused on the diversity and complexity of sodium channel localization, composition, and regulation, in addition to the multifunctionality of the sodium channel complex. Increasing evidence now points to sodium channel functions other than the classically well-described electrical effects secondary to influx of sodium ions into the cardiomyocyte, which may explain the observed phenotypic diversity observed in *SCN5A* mutation carriers (*Figure [4](#cvaa082-F4){ref-type="fig"}*). Based on the evidence we presented, we propose that sodium channel (dys)function and its consequences may now be categorized into (i) direct ionic effects of sodium influx through Na~V~1.5 on membrane potential and consequent action potential generation, (ii) indirect ionic effects of sodium influx on intracellular homeostasis and signalling, and (iii) non-ionic effects of Na~V~1.5, independent of sodium influx, through interactions with macromolecular complexes within the different microdomains of the cardiomyocyte. These indirect ionic and non-ionic processes may, acting alone or in concert, contribute significantly to arrhythmogenesis in inherited sodium channel (dys)function. Hence, further exploration of these multifunctional effects of Na~V~1.5 will be essential for the development of novel therapeutic strategies aimed at preventing arrhythmias and sudden cardiac death not only in inherited syndromes but also in acquired diseases such as myocardial ischaemia and heart failure. Given the rapid development of highly innovative techniques, potential novel targets are expected to be identified in the (near) future.

![Novel classification of Na~V~1.5 (dys)function. The direct ionic function controls excitability by modification of membrane potential and initiation of AP. The indirect ionic function regulates calcium levels and downstream calcium signalling. The non-ionic function relies on the integrity of region-specific macromolecular complexes to control cell adhesion, cell--cell communication, signalling (other than calcium), myocardium architecture (extracellular matrix), and developmental aspects. AP, action potentials.](cvaa082f4){#cvaa082-F4}
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